Ovid Therapeutics Inc. (OVID)

NCM – Real vaqt narxi. Valyuta: USD

2.87

+0.08 (2.87%)

Yopilishda: May 12, 2026, 4:00 PM EDT

2.85

-0.02 (-0.70%)

Bozordan keyin: May 12, 2026, 7:55 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Ovid Therapeutics Inc. (OVID)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding

Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript

Here's Why Ovid Therapeutics Stock Popped Higher Today

Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally

Videolar

No Data

Press-relizlar

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Search stocks

Ovid Therapeutics Inc. (OVID)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding

Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript

Here's Why Ovid Therapeutics Stock Popped Higher Today

Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally

Videolar

No Data

Press-relizlar

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

Ovid Therapeutics Announces Pricing of $60 Million Private Placement